Ken Ogasawara

29PUBLICATIONS
52CO-AUTHORS
Applied statisticsLanguage documentation and descriptionPredictive and prognostic markersLiquid biopsiesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jun 04, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL.

|Jul 07, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Manali Kamdar, Scott R Solomon, Jon Arnason

|Jun 09, 2025
Exposure-response relationship of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Yizhe Chen, Yan Li, Yongjun Xue

|Apr 30, 2025
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.

Alison Sehgal, Daanish Hoda, Peter A Riedell

|Jan 21, 2025
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma.

Hongxiang Hu, Yan Li, Julia Piasecki

|Sep 30, 2024
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.

Yuliya Linhares, Cesar O Freytes, Mohamad Cherry

Pageof 5

Frequent Collaborators

5 joint publications

Yan Li

5 joint publications

Jeremy S Abramson

4 joint publications

Tanya Siddiqi

4 joint publications

Leo I Gordon